You are here

AdvaMed COVID Testing Supply Registry

About the National COVID-19 Supply Registry

AdvaMed has been working closely with the White House, HHS, FDA, FEMA and other key government agencies to ensure the continued supply of diagnostics tests, as well as other vital medical equipment such as PPE and ventilators, in the fight against the COVID-19 pandemic.

To further assist state and federal governments in their pandemic responses, AdvaMed has created a comprehensive, national COVID-19 diagnostic supply registry which compiles information from diagnostic companies along with publicly available data on daily tests performed to create a centralized and standardized COVID-19 diagnostic supply registry.

AdvaMed’s registry aims to help streamline communications and data sharing between diagnostic companies and federal and state governments as well as standardize test supply reporting. It also facilitates collaboration with laboratories and other public health stakeholders to optimize access to all platforms of COVID-19 testing so that any potential shortages are identified and addressed quickly.

Learn More

Topline Data as of April 2, 2021

  • The ~411M cumulative molecular COVID-19 tests shipped nationwide since March 2020 by the 14 Registry participants include ~318M commercial tests and ~93M extraction reagents​.
    • Abbott
    • BD 
    • BioMérieux 
    • Bio-Rad 
    • Beckman Coulter 
    • Cepheid 
    • Fujirebio
    • Hologic 
    • Ortho Clinical Diagnostics 
    • QIAGEN 
    • Roche Diagnostics 
    • Sekisui Diagnostics 
    • Siemens Healthineers 
    • Thermo Fisher Scientific 
       
  • Per public sources, daily molecular tests run decreased by 4% compared to the previous week, with an average of ~1.3 million2 per day last week.
     
  • Registry participants collectively shipped ~6.8 million1 molecular tests for the week ending March 20.
     
  • High-quality serology testing, authorized by FDA, remains available at scale with industry capacity to manufacture 100 million tests per month.  
     
  • Registry participants have brought antigen testing to market, though many states do not report antigen tests run.

Weekly Molecular (MDx) tests shipped3 & reported test results nationwide
 

line chart depicting steady increase over months

1 Averaged over latest 4 weeks to account for fluctuations in purchase cycles.
2 Averaged over the week to account for fluctuations by day of the week. State-reported results (molecular test result figures used where available, otherwise total test results used, which may include antigen tests).
3 Weekly average over the last 4 weeks.
4 IVD and LDT molecular diagnostic test shipments.
5 State-reported results (molecular test result figures used where available, otherwise total test results used, which may include antigen tests.)

Weekly Reporting

The registry provides weekly state- and national-level updates on the number of molecular, antigen, and serology (antibody) tests shipped in the U.S. 

weekly report